Ocumension Therapeutics
Shanghai · Founded 2017
About Ocumension Therapeutics
Ocumension Therapeutics is a China-based ophthalmic pharmaceutical platform company dedicated to identifying, developing, and commercializing first- or best-in-class ophthalmic therapies. The company’s vision is to provide a world-class pharmaceutical total solution to address significant unmet ophthalmic medical needs in China. Since the inception, Ocumension Therapeutics has focused on building a platform integrating specialized capabilities in each major functionality involved in an ophthalmic drug's development cycle, from research and development, manufacturing to commercialization. Ocumension Therapeutics believes its platform positions it well to achieve leadership in China ophthalmology, with a first-mover advantage over future competitors.
Company Facts
- Founded: 2017
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: $10K – $50K
- Total funding: $364.3M
- Funding stage: IPO
- Last round: Post-IPO Equity (Aug 2024)
- Ticker: hkg:1477
- Website: ocumension.comen
- Phone: +86 (021)-61493800
Industries & Categories
Biotechnology, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/ocumension-therapeutics-182532 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.